Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Nasopharyngeal Carcinoma 8Lung Neoplasms 7Colorectal Neoplasms 4Melanoma 3Esophageal Squamous Cell Carcinoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Osteosarcoma 2Nasopharyngeal Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Esophageal Neoplasms 2Unresectable Non-small Cell Lung Cancer 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Radiation Injuries 1Quality of Life 1Pleural Effusion, Malignant 1Non-squamous Non-small Cell Lung Cancer 1Neuroblastoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bone Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

nimotuzumab 1gimeracil 1endostar protein 1Radiotherapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal × endostar protein × Clear all
NCT02749526 2022-07-29

Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Terminated
70 enrolled
Gastrointestinal

Esophageal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡